The Latest Analyst Ratings for Mainz Biomed
Portfolio Pulse from Benzinga Insights
Mainz Biomed (NASDAQ:MYNZ) has received 4 analyst ratings in the last quarter, with 2 bullish and 2 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The 12-month price targets from these analysts average $8.0, with a high of $9.00 and a low of $5.00. This average target price remains unchanged from the previous period. Analysts rate stocks based on financial statements, meetings, and insider information, providing guidance on stock performance.
November 20, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mainz Biomed has a stable outlook from analysts with an average 12-month price target of $8.0, indicating a neutral to positive sentiment among analysts.
The consistent average price target and the recent bullish and somewhat bullish ratings suggest a stable to positive outlook for MYNZ. This could lead to a short-term positive impact on the stock price as investors may be influenced by analyst ratings.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100